KRN7000 α-半乳糖神经酰胺 α-Galactosylceramide (KRN7000)

产品描述

α-半乳糖神经酰胺的英文为α-Galactosylceramide，上海惠诚生物提供纯度≥95%的α-半乳糖神经酰胺，规格 1mg或者5mg，大包装请单独咨询。α-半乳糖神经酰胺别称KRN7000。更多请联系我们021-60498804 Product Description Synthetic. Originally isolated from the marine sponge Angelas mauritianus [1]. Immunostimulant [1, 2, 3]. Potent stimulator of natural killer T (NKT) cells [4, 5]. Specific ligand of the lipid-binding MHC class I-like protein CD1d in human and mouse NKT cells [5]. Protects against LPS-induced shock [7]. Potent antitumor compound [2, 6, 8]. Product References Synthesis of alpha-, beta-monoglycosylceramides and four diastereomers of an alpha-galactosylceramide: M. Morita, et al.; Bioorg. Med. Chem. Lett. 5, 699 (1995) Immunostimulatory and antitumor activities of monoglycosylceramides having various sugar moieties: K. Motoki, et al.; Biol. Pharm. Bull. 18, 1487 (1995) Immunostimulatory activities of monoglycosylated alpha-D-pyranosylceramides: A. Uchimura, et al.; Bioorg. Med. Chem. 5, 2245 (1997) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein: Fujii S, et al.; J. Exp. Med. 198, 267 (2003) Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides: K.O. Yu, et al.; PNAS 102, 3383 (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer: A. Ishikawa, et al.; Clin. Cancer Res. 11, 1910 (2005) Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock: G. Sireci, et al.; J. Leukoc. Biol. 81, 607 (2007) α-Galactosylceramide activates antitumor immunity against liver tumor: T. Tatsumi, et al.; Hepatol. Res. 41, 160 (2011) α-Galactosylceramide was originally isolated from an extract of the Okinawan marine sponge Agelas mauritianus . α-Galactosylceramide is a specific ligand for human and mouse natural killer T (NKT) cells and exhibits potent anti-tumor activity with murine in vivo experiments including subcutaneous implanted model and metastatic models in the liver and lung. In the liver metastatic models, treatment with α-galactosylceramide suppressed the growth of tumors and prolonged the survival term of the tumor-bearing mice. α-Galactosylceramide has been reported to show various immunological effects in infectious diseases, autoimmune disease and graft versus host disease in mice. 1 Chemically synthesized. Provided with a BSE/TSE statement. Purity by HPLC-CAD – example chromatogram on the right.